IDPH--Positive preliminary results for pivotal trial of ID Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Brad C. Dunlap who wrote (642)	4/14/1997 8:41:00 PM
From: Miljenko Zuanic	of 1762

Brad, I have talked with IDEC IR. She (lady) didn't confirmed your info that SmithKline is building second plant for CE9.1 manufacturing. Also they do not know for any reason(s) or explanation why SK sold large portion of the IDEC holding. "Rumor" about second plant do not have anything with IDEC, and they do not know who started rumor. I send e-mail to SK asking about second plant and sell-of, but I am not optimistic that I will have respond. To be objective (because CE9.1 is ISIP 2302 competitor for RA), I did ask about P III trials and other monoclonal antibody programs. As far as IDEC know, trough join committee, P III trials is ongoing normally. In all three dosage regimes there are no reports of any rash as side-reaction. Real reason(s) why SK sold IDEC share are for know unknown. Something will surface in next several weeks. Best luck to all IDEC shareholder. mz

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next